

# Carlos Brotons

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2102148/publications.pdf>

Version: 2024-02-01

88  
papers

21,265  
citations

101543  
36  
h-index

23533  
111  
g-index

130  
all docs

130  
docs citations

130  
times ranked

24689  
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2022, 29, 5-115.	1.8	220
2	Prevalence of Post COVID-19 Condition in Primary Care: A Cross Sectional Study. International Journal of Environmental Research and Public Health, 2022, 19, 1836.	2.6	18
3	Effectiveness of an Intervention Aimed at Improving Information for Patients with High Cardiovascular Risk: INFORISK Clinical Trial. International Journal of Environmental Research and Public Health, 2021, 18, 3621.	2.6	4
4	Physicochemical Properties of Lipoproteins Assessed by Nuclear Magnetic Resonance as a Predictor of Premature Cardiovascular Disease. PRESARV-SEA Study. Journal of Clinical Medicine, 2021, 10, 1379.	2.4	2
5	Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines. Clínica E Investigacióñ En Arteriosclerosis (English Edition), 2021, 33, 85-107.	0.2	4
6	Comentario del CEIPV a la actualizacióñ de las Guáas Europeas de Prevencióñ Vascular en la Práctica Clínica. Clínica E Investigacióñ En Arteriosclerosis, 2021, 33, 85-107.	0.8	1
7	Epidemiología de las hipertrigliceridemias. Clínica E Investigacióñ En Arteriosclerosis, 2021, 33, 7-13.	0.8	1
8	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
9	Practical Decision Algorithms for the Use of the Cardiovascular Polypill in Secondary Prevention in Europe. Frontiers in Cardiovascular Medicine, 2021, 8, 663361.	2.4	3
10	Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AECEAN STUDY): A Randomized Clinical Trial. American Journal of Cardiovascular Drugs, 2020, 20, 61-71.	2.2	22
11	Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2020, 27, 181-205.	1.8	148
12	Healthy habits and risk factors of parents can have long-term clinical consequences in their offspring. European Journal of Preventive Cardiology, 2020, ,.	1.8	1
13	Estimation of Lifetime Risk of Cardiovascular Disease (IBERLIFERISK): A New Tool for Cardiovascular Disease Prevention in Primary Care. Revista Espanola De Cardiología (English Ed ), 2019, 72, 562-568.	0.6	7
14	Predictive validity of the risk SCORE model in a Mediterranean population with dyslipidemia. Atherosclerosis, 2019, 290, 80-86.	0.8	11
15	Epidemiology, risk factors, and opportunities for prevention of cardiovascular disease in individuals of South Asian ethnicity living in Europe. Atherosclerosis, 2019, 286, 105-113.	0.8	40
16	Unprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) Consortium. Annals of Internal Medicine, 2019, 171, 756.	3.9	227
17	Lifestyle behaviours in patients with established cardiovascular diseases: a European observational study. BMC Family Practice, 2019, 20, 162.	2.9	4
18	Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?. European Heart Journal, 2019, 40, 1643-1650.	2.2	72

#	ARTICLE	IF	CITATIONS
19	Homogenization of the lipid profile values. Clínica E Investigación En Arteriosclerosis (English) Tj ETQql 1 0.784314 rgBT /Overlock 10	0.2	10
20	Homogeneización de los valores del perfil lipídico. Clínica E Investigación En Arteriosclerosis, 2018, 30, 36-48.	0.8	9
21	El informe analítico ideal del perfil lipídico. Necesidad de un consenso. Revista Española De Cardiología, 2018, 71, 512-514.	1.2	22
22	Main messages for primary care from the 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of General Practice, 2018, 24, 51-56.	2.0	36
23	Nalmefene, Given as Needed, in the Routine Treatment of Patients with Alcohol Dependence: An Interventional, Open-Label Study in Primary Care. European Addiction Research, 2018, 24, 293-303.	2.4	15
24	Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy. Journal of Diabetes Research, 2018, 2018, 1-12.	2.3	24
25	Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 392, 1036-1046.	13.7	619
26	The Ideal Lipid Report: A Need for Consensus. Revista Española De Cardiología (English Ed ), 2018, 71, 512-514.	0.6	1
27	Association Between Improvement in Cardiovascular Risk Profile and Changes in Sickness Absence: Results of the ICARIA Study. Revista Española De Cardiología (English Ed ), 2017, 70, 941-951.	0.6	1
28	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. BMC Medicine, 2017, 15, 173.	5.5	24
29	Perception of preventive care and readiness for lifestyle change in rural and urban patients in Poland: a questionnaire study. Annals of Agricultural and Environmental Medicine, 2017, 24, 732-738.	1.0	6
30	Concordance between two methods in measuring treatment adherence in patients with type 2 diabetes. Patient Preference and Adherence, 2016, 10, 743.	1.8	4
31	Clinical consequences of using the new cardiovascular risk tables SCORE OP in patients aged over 65 years. Medicina Clínica (English Edition), 2016, 147, 381-386.	0.2	7
32	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2016, 37, 2315-2381.	2.2	5,370
33	Evaluación de las nuevas tablas de riesgo cardiovascular SCORE OP para pacientes mayores de 65 años. Revista Española De Cardiología, 2016, 69, 981-983.	1.2	17
34	2016 European Guidelines on cardiovascular disease prevention in clinical practice. Atherosclerosis, 2016, 252, 207-274.	0.8	415
35	Assessment of the New SCORE OP Cardiovascular Risk Charts in Patients Older Than 65 Years. Revista Española De Cardiología (English Ed ), 2016, 69, 981-983.	0.6	7
36	2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Journal of Preventive Cardiology, 2016, 23, NP1-NP96.	1.8	683

#	ARTICLE	IF	CITATIONS
37	Comparison of application of different methods to estimate lifetime cardiovascular risk. European Journal of Preventive Cardiology, 2016, 23, 564-571.	1.8	8
38	Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial. Gynecological Endocrinology, 2016, 32, 477-482.	1.7	21
39	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 2016, 37, 267-315.	2.2	5,890
40	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 1125.	0.6	57
41	The ERICE-score: the New Native Cardiovascular Score for the Low-risk and Aged Mediterranean Population of Spain. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 205-215.	0.6	12
42	La ecuaciÃ³n ERICE: la nueva ecuaciÃ³n autÃ³ctona de riesgo cardiovascular para una poblaciÃ³n mediterrÃ¡nea envejecida y de bajo riesgo en EspaÃ±a. Revista Espanola De Cardiologia, 2015, 68, 205-215.	1.2	32
43	A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?. American Journal of Cardiovascular Drugs, 2015, 15, 113-133.	2.2	41
44	Impact of the New American and British Guidelines on the Management and Treatment of Dyslipidemia in a Spanish Working Population. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 906-911.	0.6	5
45	A Polypill Strategy to Improve Adherence. Journal of the American College of Cardiology, 2014, 64, 2071-2082.	2.8	290
46	Impacto de las nuevas guÃAs estadounidense y britÃjnica en el manejo y el tratamiento de las dislipemias en una poblaciÃ³n laboral espaÃ±ola. Revista Espanola De Cardiologia, 2014, 67, 906-911.	1.2	6
47	Impacto de la utilizaciÃ³n de las diferentes tablas SCORE en el cÃ¡lculo del riesgo cardiovascular. Revista Espanola De Cardiologia, 2014, 67, 94-100.	1.2	26
48	Impact of Using Different SCORE Tables for Estimating Cardiovascular Risk. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 94-100.	0.6	6
49	Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care. BMC Family Practice, 2013, 14, 36.	2.9	38
50	Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region. Bone, 2013, 52, 557-561.	2.9	30
51	Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. European Journal of Preventive Cardiology, 2013, 20, 1095-1105.	1.8	25
52	Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. European Journal of Preventive Cardiology, 2013, 20, 1022-1030.	1.8	53
53	Benchmarking Is Associated With Improved Quality of Care in Type 2 Diabetes. Diabetes Care, 2013, 36, 3388-3395.	8.6	46
54	Attitudes toward preventive services and lifestyle: the views of primary care patients in Europe. The EUROPREVIEW patient study. Family Practice, 2012, 29, i168-i176.	1.9	53

#	ARTICLE	IF	CITATIONS
55	Beliefs and attitudes to lifestyle, nutrition and physical activity: the views of patients in Europe. Family Practice, 2012, 29, i49-i55.	1.9	18
56	Los nuevos marcadores de riesgo cardiovascular: ¿de dónde venimos, dónde estamos, hacia donde vamos?. Clínica E Investigación En Arteriosclerosis, 2012, 24, 89-91.	0.8	1
57	Beneficios del uso de un dispositivo de gestión de datos del glucómetro en el seguimiento de pacientes con diabetes tipo 2 en atención primaria: estudio TRANSFER. Avances En Diabetología, 2012, 28, 70-76.	0.1	1
58	Ensayo clínico aleatorizado para evaluar la eficacia de un programa integral de prevención secundaria de las enfermedades cardiovasculares en atención primaria: estudio PREseAP. Revista Española De Cardiología, 2011, 64, 13-20.	1.2	29
59	Randomized Clinical Trial to Assess the Efficacy of a Comprehensive Programme of Secondary Prevention of Cardiovascular Disease in General Practice: The PREseAP Study. Revista Española De Cardiología (English Ed ), 2011, 64, 13-20.	0.6	13
60	Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus. Cardiovascular Diabetology, 2011, 10, 82.	6.8	12
61	Multicenter Cluster-Randomized Trial of a Multifactorial Intervention to Improve Antihypertensive Medication Adherence and Blood Pressure Control Among Patients at High Cardiovascular Risk (The) Tj ETQq1 1 0.784314 rGBT /Overl...	0.784314 rGBT /Overl...	0
62	EUROPREVIEW study and Wonca Europe conference. European Journal of General Practice, 2010, 16, 122-122.	2.0	0
63	Effectiveness of a geriatric intervention in primary care: a randomized clinical trial. Family Practice, 2010, 27, 239-245.	1.9	69
64	Improvements in Health-Related Quality of Life of Patients Admitted for Heart Failure. The HF-QoL Study. Revista Española De Cardiología (English Ed ), 2010, 63, 668-676.	0.6	4
65	Evolución de la calidad de vida relacionada con la salud en pacientes ingresados por insuficiencia cardíaca. Estudio IC-QoL. Revista Española De Cardiología, 2010, 63, 668-676.	1.2	10
66	EUROPREV asks patients about preventive services. European Journal of General Practice, 2010, 16, 59-59.	2.0	0
67	Lipid Treatment Assessment Project 2. Circulation, 2009, 120, 28-34.	1.6	293
68	Randomized Clinical Trial of the Effectiveness of a Home-Based Intervention in Patients With Heart Failure: The IC-DOM Study. Revista Española De Cardiología (English Ed ), 2009, 62, 400-408.	0.6	19
69	Health-related quality of life in unselected outpatients with heart failure across Spain in two different health care levels. Magnitude and determinants of impairment: The INCA study. Quality of Life Research, 2008, 17, 1229-1238.	3.1	31
70	Factors Affecting the Control of Blood Pressure and Lipid Levels in Patients With Cardiovascular Disease: The PREseAP Study. Revista Española De Cardiología (English Ed ), 2008, 61, 317-321.	0.6	7
71	Predictión de la glucemia basal alterada y resistencia a la insulina mediante el uso de medidas antropométricas de adiposidad central: estudio PRED-IR. Medicina Clínica, 2008, 131, 366-370.	0.6	15
72	Health Economic Evaluation of Low-Dose Acetylsalicylic Acid in the Primary Prevention of Cardiovascular Disease. Revista Española De Cardiología (English Ed ), 2006, 59, 807-815.	0.6	2

#	ARTICLE	IF	CITATIONS
73	The association between leptin and left ventricular hypertrophy: a population-based cross-sectional study. <i>Journal of Hypertension</i> , 2006, 24, 1447.	0.5	4
74	Consequences of using different methods to assess cardiovascular risk in primary care. <i>Family Practice</i> , 2006, 23, 28-33.	1.9	33
75	Prevention and health promotion in clinical practice: the views of general practitioners in Europe. <i>Preventive Medicine</i> , 2005, 40, 595-601.	3.4	249
76	European guidelines on cardiovascular disease prevention in clinical practice. <i>Atherosclerosis</i> , 2003, 171, 145-155.	0.8	106
77	New European guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of General Practice</i> , 2003, 9, 124-125.	2.0	4
78	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Heart Journal</i> , 2003, 24, 1601-1610.	2.2	1,588
79	Prophylactic treatment after myocardial infarction in primary care: how far can we go?. <i>Family Practice</i> , 2003, 20, 32-35.	1.9	22
80	The association between leptin and left ventricular hypertrophy. <i>Journal of Hypertension</i> , 2003, 21, 1467-1473.	0.5	36
81	Dietary advice in clinical practice: the views of general practitioners in Europe. <i>American Journal of Clinical Nutrition</i> , 2003, 77, 1048S-1051S.	4.7	53
82	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S78.	2.8	174
83	European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003, 10, S1-S10.	2.8	152
84	Perceived Health over 3 Years after Percutaneous Coronary Balloon Angioplasty. <i>Journal of Clinical Epidemiology</i> , 1999, 52, 615-623.	5.0	11
85	Pacientes con s <sup>í</sup> ndrome coronario agudo: abordaje terapéutico (patrones de manejo) y pronóstico al año en un hospital general terciario. <i>Revista Espanola De Cardiologia</i> , 1998, 51, 954-964.	1.2	16
86	Worldwide distribution of blood lipids and lipoproteins in childhood and adolescence: a review study. <i>Atherosclerosis</i> , 1998, 139, 1-9.	0.8	73
87	Predisposing Factors and Prognostic Value of Sustained Monomorphic Ventricular Tachycardia in the Early Phase of Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 1996, 28, 1670-1676.	2.8	77
88	Evaluation of preventive and health promotion activities in 166 primary care practices in Spain. <i>Family Practice</i> , 1996, 13, 144-151.	1.9	18